Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986224 · 2 trials · 3 indications
Part 1 only
Part 1 only
Part 1 only
| Arm | Type | Description |
|---|---|---|
| Normal Renal Function | EXPERIMENTAL | - |
| Mild Renal Impairment | EXPERIMENTAL | - |
| Moderate Renal Impairment | EXPERIMENTAL | - |
| Severe Renal Impairment | EXPERIMENTAL | - |
| End-Stage Renal Disease (ESRD) | EXPERIMENTAL | ESRD participants and are on chronic hemodialysis |
| Rifampin + BMS-986224 | EXPERIMENTAL | Oral administration |
| Name | Type | Description |
|---|---|---|
| BMS-986224 | DRUG | Specified dose on specified days |
| Rifampin | DRUG | Specified dose on specified days |
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * BMI ≥18 and ≤ 35kg/m2 * Systolic blood pressure \>100 mmHg Exclusion Criteria: * Women of childbearing potential or women who are currently pregnant * Clin...
BMS-986224 is an investigational small molecule being developed by Bristol-Myers Squibb for cardiovascular conditions, specifically studied in healthy participants and in participants with cardiac failure or myocardial failure. It is currently in Phase 1 clinical development and is not approved by the FDA.
The molecular target of BMS-986224 has not been disclosed in available clinical trial information. The drug is being studied for its effects in cardiovascular conditions, but its specific mechanism of action is not publicly detailed.
BMS-986224 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company is conducting Phase 1 clinical trials to evaluate the drug in healthy participants and in those with cardiac failure.
BMS-986224 is in Phase 1 clinical development. Two Phase 1 trials have been completed, both in the United States, with a total enrollment of 50 participants. The drug is investigational and has not received FDA approval.
BMS-986224 has two completed Phase 1 trials: NCT03563950, a study of the effect of rifampin on a single dose of BMS-986224 in healthy participants (enrollment 42), and NCT03634969, a study of BMS-986224 in renally impaired participants with cardiac failure or myocardial failure (enrollment 50).
No alternative names for BMS-986224 have been disclosed. The drug is identified solely by its development code BMS-986224 in clinical trial registrations and is not known to be marketed under any other name.